Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012005267
Ticker NVS
Company NOVARTIS
Currency $
Price
Aware Investor Index (AII) 2.4144
Recommendation BUY
P/E 21.91
ROE 13.04 %
Capitalization 212,133,370,000 $
Dividend Yield 3.21 %
P/S 4.32
AII Position 206
P/E Position 325
ROE Position 271
Capitalization Position 37
Dividend Yield Position 238
Sales 49,109,000,000 $
10-Year Average Earnings 9,680,800,000 $
Shares Outstanding 2,371,000,000
Equity 74,227,000,000 $
Dividend per Share 2.87 $
Industry Pharmaceutical
Country Switzerland
NOVARTIS Investor Relations Web Site http://www.novartis.com/investors/index.shtml







Sales:

YEAR MONTH AMOUNT
2017 12 49,109,000,000.00 $
2016 12 48,518,000,000.00 $
2015 12 49,414,000,000.00 $
2014 12 52,180,000,000.00 $
2013 12 51,869,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 7,703,000,000.00 $
2016 12 6,698,000,000.00 $
2015 12 17,794,000,000.00 $
2014 12 10,280,000,000.00 $
2013 12 9,292,000,000.00 $
2012 12 9,383,000,000.00 $
2011 12 9,072,000,000.00 $
2010 12 9,969,000,000.00 $
2009 12 8,454,000,000.00 $
2008 12 8,163,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 74,227,000,000.00 $
2016 12 74,891,000,000.00 $
2015 12 77,122,000,000.00 $
2014 12 70,884,000,000.00 $
2013 12 74,472,000,000.00 $
2012 12 69,219,000,000.00 $
2011 12 65,940,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 2,371,000,000
2016 12 2,400,000,000
2015 12 2,438,000,000
2014 12 2,470,000,000
2013 12 2,479,000,000
2012 12 2,418,145,330
2011 12 2,406,700,000

 












Bloomberg News for NOVARTIS:



Google News for NOVARTIS:

Mayfield Recorder - 7 hours ago
Elefante Mark B Has $799000 Stock Position in Novartis AG (NYSE ...
Elefante Mark B boosted its position in shares of Novartis AG (NYSE:NVS) by 3.6% in the second quarter, according to its most recent filing with ...
DXC News
Top scientist categorically denies any wrongdoing in Novartis data ...
Top scientist categorically denies any wrongdoing in Novartis data ... 6, an FDA official said Novartis appeared to have been aware of ...
Riverton Roll
Novartis Ag (NVS): A Look Behind The Numbers
Novartis Ag (NVS) shares are on chartist's watch as the stock is edging below the MACD Histogram zero line. Current levels place the share ...
Stock Minute
Novartis AG (NYSE:NVS) Watches Shares Move with 1.16880682 ...
On a typical market day there is no shortage of stock news. Investors are often tasked with trying to decipher which news is worth paying ...
STAT - 22 hours ago
Tracking the Target Price for Novartis AG (NYSE:NVS)
Zooming in on shares of Novartis AG (NYSE:NVS), we note that the average target price is presently $100.67. This is the consensus target ...
Glenrock Gazette - 10 hours ago
Novartis AG (NYSE:NVS) Shares Sold by Buckingham Asset ...
Buckingham Asset Management LLC trimmed its holdings in shares of Novartis AG (NYSE:NVS) by 1.0% during the second quarter, according ...
Stock Snacks - 20 minutes ago
Cookson Peirce & Co. Inc. Raises Holdings in Novartis AG (NYSE ...
Cookson Peirce & Co. Inc. boosted its stake in Novartis AG (NYSE:NVS) by 122.2% during the 2nd quarter, according to the company in its ...
Stock News X - 1 day ago
Glancy Prongay & Murray LLP Continues its Investigation on Behalf ...
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) ...
Mayfield Recorder - 5 hours ago
Sell Trend Alert Handed to Novartis Ag (NVS) With $89.75 The ...
Novartis Ag (NVS) currently has a 50-day moving average of 90.98, the 200-day is at 82.1, and the 7-day is 90.19. In the investing realm, using ...
Riverton Roll - 1 hour ago
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Novartis (NVS), but is the stock performing well in comparison to the rest of its ...


Back